Advancing new treatments for skin disease and infections

Dermatology company leveraging the unique properties of synthetic cannabinoids with its Permetrex™ technology

Promising R&D, with a rapidly advancing pipeline of dermatology and antimicrobial products

World-class team with extensive cannabinoid drug development and commercialisation expertise

A leader in topical drug development

Botanix Pharmaceuticals Limited is an ASX-listed dermatology focused company based in Perth (Australia) and Philadelphia (USA) committed to the development of novel treatments for common skin diseases and infections that are underpinned by science and supported by well-controlled, randomised clinical trials.

Botanix leverages the unique anti-inflammatory and antimicrobial properties of synthetic cannabidiol (CBD), and utilises its proprietary drug delivery system, Permetrex™️, across all programs.

Botanix has attracted a world-class team and significant capital to support the progression of its products. We are moving quickly, but never at the expense of our rigorous commitment to ethical research and development (R&D) and the highest clinical standards mandated by the US Food and Drug Administration (FDA).

Check out our latest news

DEAL NEWS | Pfizer enters CBD market

At Botanix, we genuinely believe in the therapeutic potential…

AMR: the next global pandemic?

While the world continues to battle COVID-19, experts are concerned…

Investor Roadshow Presentation

Botanix has today released an updated corporate presentation…


According to WHO Director-General Tedros Adhanom Ghebreyesus,…

MEET THE TEAM | Lynda Berne, Head of Commercial

With a successful track record of commercialising therapies…

AGM Presentation

Botanix Pharmaceuticals (ASX:BOT) is today hosting its Annual…

Vince Ippolito speaks with Proactive

Botanix President and Executive Chairman, Vince Ippolito, was…

Dermatology Update

Botanix Pharmaceuticals (ASX:BOT) has today provided an update…

Invest in innovation

Botanix Pharmaceuticals offers a compelling opportunity for investors who are interested in capitalising on the significant market for dermatology products. Our novel Permetrex™ delivery technology combined with drugs (including cannabidiol or CBD) that exhibit novel mechanisms of action, create promising new product opportunities in dermatology. Our clinical trials to date have highlighted the unique mechanism of action which drives synthetic cannabidiol to produce anti-inflammatory and antimicrobial effects. We are leveraging this evidence to inform the development of new pharmaceutical products, targeting some of the most underserved and lucrative segments of the global healthcare market. Already, we have one of the most advanced clinical pipelines for synthetic cannabinoids in the world.

New treatments, in demand

Botanix has generated strong scientific support for the anti-inflammatory and antimicrobial mechanisms of action of synthetic cannabinoids with application in the development of novel dermatology and bacteria fighting applications.

There have been no new chemical entities (NCE’s) in topical drugs approved for acne in more than two decades and resistance to available antibiotics remains a significant global issue, with no new classes of antibiotics approved in more than three decades. When bacteria survive exposure to antibiotics that would normally eliminate them, these surviving bacteria grow and spread resistance, leading to the emergence of ‘superbugs’. New treatments in dermatology and anti-microbials are needed now.

Botanix periodically runs clinical studies in Australia, New Zealand and the USA. Please share your details if you would like to learn more.

Sign up to receive our latest news

Thank you! Your subscription has been confirmed. You'll hear from us soon.